Novo Nordisk: Trial information of oral weight-loss drug similar to Wegovy – ET HealthWorld

0
4
Novo Nordisk: Trial information of oral weight-loss drug similar to Wegovy – ET HealthWorld


Copenhagen: Novo Nordisk stated on Monday information from a late-stage trial confirmed an oral model of its drug semaglutide for weight reduction helped obese or overweight adults lose on common between 15-17 per cent of their physique weight, similar to its Wegovy injection.

The outcomes are one other increase for Novo Nordisk whose weekly Wegovy injection has remodeled the weight-loss market since its US launch in June 2021, capturing the eye of sufferers, buyers and even celebrities worldwide.

The Danish drugmaker stated in an announcement that the headline outcomes have been statistically vital and confirmed superior weight reduction when in comparison with a placebo.

It expects to file an utility for the each day pill for regulatory approval in america and the European Union in 2023.

A world launch of the oral 50 milligram (mg) semaglutide drug is contingent on portfolio prioritisations and manufacturing capability, the corporate added with out giving additional particulars.

The Section IIIa research throughout the so-called OASIS programme concerned 667 adults with weight problems or who have been obese with a number of comorbidities. The remedy was along side way of life intervention.

Contributors who adhered to the remedy on common skilled a weight lack of 17.4 per cent after 68 weeks in contrast with only one.8 per cent of the those who took the placebo, Novo stated.

These contributors who did not totally adhere to the remedy achieved a weight lack of 15.1 per cent in comparison with a discount of two.4 per cent with placebo.

The outcomes are similar to the corporate’s Wegovy injection, stated Martin Holst Lange, head of growth at Novo Nordisk. That results in round 15 per cent weight reduction on common, alongside eating regimen and train modifications.

“The selection between a each day pill or weekly injection for weight problems has the potential to supply sufferers and healthcare suppliers the chance to decide on what most accurately fits particular person remedy preferences,” he added.

Whereas extensively anticipated, the results of the research was a reassuring end result given the threats of future aggressive medicine, Jefferies wrote in a observe to purchasers.

Gross sales of the 50 mg drug may rise to $8 billion a yr, the brokerage estimated. The drug appeared to have a “protected and well-tolerated profile”, with the most typical hostile impression being gentle to average gastrointestinal results that diminished over time, Novo Nordisk stated.

Novo Nordisk has had provide points and struggled to maintain up with hovering US demand for Wegovy. The bottom dose of the weekly Wegovy injection comprises simply 2.4 mg of semaglutide, whereas the each day tablet comprises 50 mg.

A spokesperson declined to touch upon manufacturing capability of the tablet, however the firm is prioritising US provides of Wegovy over launching in new markets.

  • Printed On Could 23, 2023 at 10:35 AM IST

Be part of the neighborhood of 2M+ business professionals

Subscribe to our publication to get newest insights & evaluation.

Obtain ETHealthworld App

  • Get Realtime updates
  • Save your favorite articles


Scan to obtain App




Supply hyperlink

LEAVE A REPLY

Please enter your comment!
Please enter your name here